Estimating Prices for R&D Investment in the 2007 R&D Satellite Account

This paper is part of a series that provides the details behind the Bureau of Economic Analysis's (BEA) satellite account on research and development (R&D) activity. In the current work, the focus is on the theoretical underpinnings and empirical implementation of the R&D price index used to construct real R&D output. We examine four alternative price indexes. For each, we lay out the theoretical assumptions needed for the approach to be valid and examine how well the approach works in practice. We then compare these four alternative price indexes and explain the choice of our preferred price index.

Innovation in the European chemical industry

Firms in the European chemical industry have been among the most successful firms world wide. However, they have had to undertake severe restucturing in order to maintain their market position. These efforts focused in particular on strengthening their innovative capability as product and process innovation have become the most decisive factors in global competition. In order to improve the innovative conditions, the European Commission has supported the Community Innovation Survey (CIS). 1992/1993 was the first time that large-scale harmonised innovation surveys were carried out in all Member States of the European Union. This study uses the CIS micro data from nearly 2000 European chemical firms. This study focuses on the identification of innovative trends within the chemical industry between 1984 and 1993. Using data from annual reports of nine selected European stock companies, the study identifies those areas of the chemical industry currently having the highest innovative potential. Three speciality categories are identified as having the highest number of innovations during this ten year period: chemicals, paints/varnishes, and plastics. -- Obwohl viele europäische Unternehmen der chemischen Industrie in den vergangenen Jahrzehnten zu den erfolgreichsten in der Welt zählten, mußten sie sich Anfang der neunziger Jahre einem gravierenden Strukturwandel unterziehen, um ihre Position behaupten zu können. Die Fähigkeit der Unternehmen, Innovationen hervorzubringen, stand und steht dabei im Mittelpunkt. Mit dem Ziel, die Rahmenbedingungen für Innovationen zu verbessern, führte die EU-Kommission 1993 eine europaweite Innovationserhebung, den Community Innovation Survey (CIS) durch. In dieser Studie wurden die anonymisierten Antworten von nahezu 2000 Unternehmen der chemischen Industrie analysiert. Um Innovationstrends aufzuzeigen zu können, wurden darüber hinaus Geschäftsberichte von neun großen europäischen Chemieunternehmen ausgewertet. So wurden die Sparten Spezialitäten, Farben/Lacke und Kunststoffe als diejenigen Sparten identifiziert, die im Untersuchungszeitraum (1984-1993) die meisten Innovationen aufwiesen.

Valuation implications of pharmaceutical companies' R&D regulatory approval notifications

This paper examines shareholder wealth effects surrounding applications to, and approvals by, the United States Food and Drug Administration (FDA) for firms listed on the New York (NYSE) and London (LSE) stock exchanges. Applications to the FDA for drug approvals significantly increase shareholder wealth for NYSE firms only. The increase is driven by applications for enhancements to existing drugs, with the market anticipating the application, thus suggesting information leakage. FDA approvals also significantly increase shareholder wealth in both markets. However, there is no evidence of information leakage and the significant post-event abnormal returns support the attention-grabbing hypothesis. Enhanced drug approvals are value-relevant for both markets, which highlights the contribution of real-options to firm value

Returns on R&D investment: A comprehensive survey on the magnitude and evaluation methodologies

As technology and innovation seem to be contingent upon each other a great deal of attention has been given to the importance of assessing the contribution of R&D investment to firm and industry performance and, ultimately, to the economic performance of countries and regions. In industrialised societies not only private but also public agents have allocated increasing amounts of their resources to R&D activities, often considered the key path to innovativeness. At the same time, due to advances in empirical research, increasingly more focused on the micro (firms) rather than on the macro (country) level, old myths about the relationship between R&D, innovation and success began to fall down. Firstly, the idea that innovation is much broader than R&D has gained large support and has made it possible to identify other sources of innovation, beyond excellence in R&D, which had been largely hidden or neglected. As result, perceptions about small firms - or the so-called low-tech industries, which either do not carry out any significant R&D activities or are likely to perform them outside formal classifications - started to change. Secondly, the idea that more R&D investment is always automatically bond to success - whatever criteria one may choose to define success – has become nothing more than a utopia. In this paper we carry out an analysis of the literature on the magnitude and evaluation of R&D, and, possibly, of innovation. We identify the methodologies used and analyse to what extent the magnitude of (eventual) R&D returns is dependent on the methodology pursued and the level of analysis - firms (micro), industry (meso), and regions/countries (macro) - considered. We conclude that methodological approaches and levels of analysis determine, to a certain extent, the type of results obtained and, thus, variances between them.Innovations and R&D indicators; Methodologies; Macro, meso and micro levels; R&D payoff

Longitudinal Study on the Performance of U.S. Pharmaceutical Firms: The Increasing Role of Marketing

Nowadays, the U.S. pharmaceutical industry has been under thorough scrutiny. Popular press claims of intensive marketing activities that go beyond R&D, the strong increase of me-too drugs, and, at the same time, the high industry profitability have contributed to public skepticism. Despite this increasing role of marketing, studies on the profitability of pharmaceutical firms mainly focus on the role of R&D. In this paper, we investigate the impact of advertising and product differentiation on pharmaceutical firms’ market value over the period 1971-2005. Especially, we examine whether there has been a change in the pattern of returns in these variables over this period. Our results show that, nowadays, pharmaceutical firms’ performance is not only closely linked to their R&D activities but also to marketing activities such as advertising and product differentiation. Since the 1990s, the return of advertising has become three times larger than that of R&D. In addition, we found that the impact of product differentiation came largely from the introduction of the so called incrementally modified drugs (IMD). The vast increase of the number of IMDs since the 1990s is likely to contribute to this development. Our results emphasize the role of advertising and product differentiation in the virtuous rent-seeking behavior in the pharmaceutical industry.Marketing;Panel data;Advertising;Market value;Pharmaceutical industry;Product differentiation

Consolidation and Innovation in the Pharmaceutical Industry: The Role of Mergers and Acquisitions in the Current Innovation Ecosystem

Recent changes in the pharmaceutical industry have spurred an unprecedented wave of mergers and acquisitions. Some researchers and agencies have questioned whether pharmaceutical consolidation could impede drug innovation. However, as I explain in this Article, these concerns are largely based on an outdated understanding of the drug innovation ecosystem. Whereas a few decades ago almost all drug discovery took place inside traditional pharmaceutical companies, today most drug innovation is externally-sourced from biotech companies and smaller firms. Internal R&D is no longer the primary source, or even an important source, of drug innovation. As a result, analyses that focus on the impacts of pharmaceutical consolidation on internal drug innovation are incomplete and missing the point. Instead, merger analyses should examine whether consolidation increases demand for externally-sourced innovation and, ultimately, strengthens aggregate drug innovation

R&D and Productivity Growth: Comparing Japanese and U.S. Manufacturing Firms

We compute rates of growth in labor productivity during the 1973-80 period for samples of individual manufacturing firms, in both Japan and the U.S., and relate them to differences in the rates of growth in their capital-labor ratios and in their intensities of R&D effort. Japanese firms spent about as much of their own money on R&D, relative to sales, as did similar U.S.firms. An econometric analysis of R&D performing firms leads to the acceptance of the hypothesis that the contribution of such expenditures to productivity growth was about the same in both countries. Hence, the rather large differences on the observed rates of productivity growth between the two countries can not be accounted for by differences in either the intensity or fecundity of such expenditures. We do find two important differences between the two countries which help to explain a significant fraction of the observed differences in productivity but require in turn, an explanation of their own: 1) Japanese firms reduced their employment levels significantly during this period while US firms were increasing theirs. This, by itself, accounts for the twice as fast growth in capital-labor ratio in Japanese manufacturing. 2) The estimated effect of the growth in the capital-labor ratio on firm productivity is approximately twice as large in Japan than in the US. The two factors together can account for about half of the observed differences in the average rates of productivity growth between the two countries.